Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Depreciation & Amortization (CF) (2019 - 2025)

BridgeBio Pharma's Depreciation & Amortization (CF) history spans 7 years, with the latest figure at $1.4 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 4.97% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $5.4 million, down 10.55%, while the annual FY2025 figure was $5.4 million, 10.55% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $1.4 million at BridgeBio Pharma, up from $1.4 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $3.5 million in Q2 2021 and bottomed at $265000.0 in Q3 2021.
  • The 5-year median for Depreciation & Amortization (CF) is $1.6 million (2022), against an average of $1.5 million.
  • The largest YoY upside for Depreciation & Amortization (CF) was 520.75% in 2022 against a maximum downside of 54.62% in 2022.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $1.5 million in 2021, then rose by 8.78% to $1.7 million in 2022, then fell by 4.52% to $1.6 million in 2023, then decreased by 13.75% to $1.4 million in 2024, then grew by 4.97% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Depreciation & Amortization (CF) are $1.4 million (Q4 2025), $1.4 million (Q3 2025), and $1.3 million (Q2 2025).